Read on Twitter
Some #ASH20 DLBCL thoughts and observations. I feel like we are at the tip of a changing landscape for therapy and trial design in DLBCL, both newly dx and R/R. #lymsm
There is emerging data for non-chemo options in DLBCL (e.g. smart start, VIPOR, bi-specifics); options for the elderly/unfit? Some concerns mentioned about randomizing vs. R-miniCHOP due to pt preference. Randomized multi-arm of non-chemo regimens? #ASH20 #lymsm #lymphoma
Sequencing and/or therapy selection in R/R DLBCL. Where do CAR-T vs. ASCT vs. bi-specific vs. target agents fit? What is R/R population for future trial design? "Transplant ineligible" inclusion criteria will not mean what it did 5 years ago. #lymsm #ASH20
MRD, radiomics, ctDNA, genomics, etc will play a role in therapy selection in R/R (and frontline) DLBCL. However the therapies are outpacing the translation to the clinic of these techniques. Need to continue to move towards standardization of these tools. #lymsm #ASH20
It's much easier to find/show prognostic features vs moving them into clinical practice. How do we prioritize? Large data pooling projects are difficult due to IP, DTAs/legal hurdle, lack of funding. But needed to generate quality models and clinical level tools. #lymsm #ASH20
